Dr. Gerberding joined the FNIH as CEO on May 16, 2022. She served before that as chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co., Inc. She was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.

Previously, Dr. Gerberding was Director of the U.S. Centers for Disease Control and Prevention, where she led the agency through 40 emergency responses to public health crises, including the SARS-CoV-1 outbreak. She serves on the boards of Cerner Corporation, Case Western Reserve University, AfterNext HealthTech, and HilleVax. She also co-chairs the Center for Strategic and International Studies Commission on Strengthening America’s Health Security.

Dr. Gerberding received her undergraduate and MD degrees from Case Western Reserve University and a Masters of Public Health at the University of California, Berkeley. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine.